Loading cancer entity…
Loading cancer entity…
Clinical trials
125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (24)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | recruiting | Phase 3 | 150 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT06137144 | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.(PRIMAVERA) | recruiting | Phase 1 / Phase 2 | 161 | AstraZenecaINDUSTRY |
| 11 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT06724237 | Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | recruiting | Phase 3 | 294 | Eastern Cooperative Oncology GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT06393738 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | recruiting | Phase 1 | 329 | Arvinas Inc.INDUSTRY | 5 | Sep 4, 2026 | clinicaltrials |
| NCT04803201 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 170 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07278856 | Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas | recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05978141 | A Registry for People With T-cell Lymphoma | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04234048 | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 46 | SciTech Development, Inc.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials